Predictive Oncology Inc (POAI) - Total Liabilities
Based on the latest financial reports, Predictive Oncology Inc (POAI) has total liabilities worth $80.57 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Predictive Oncology Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Predictive Oncology Inc - Total Liabilities Trend (2008–2024)
This chart illustrates how Predictive Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Predictive Oncology Inc's balance sheet.
Predictive Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Predictive Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IQuest Co. Ltd.
KQ:262840
|
Korea | ₩50.89 Billion |
|
GUH Holdings Bhd
KLSE:3247
|
Malaysia | RM225.11 Million |
|
Woojin I&S Co Ltd
KO:010400
|
Korea | ₩25.51 Billion |
|
SciDev Limited
F:INFA
|
Germany | €25.18 Million |
|
Arima Communications Corp
TW:8101
|
Taiwan | NT$270.69 Million |
|
Sensei Biotherapeutics Inc
NASDAQ:SNSE
|
USA | $14.19 Million |
|
Haily Group Bhd
KLSE:0237
|
Malaysia | RM131.88 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Predictive Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See POAI equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 25.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Predictive Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Predictive Oncology Inc (2008–2024)
The table below shows the annual total liabilities of Predictive Oncology Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.18 Million | -15.79% |
| 2023-12-31 | $6.15 Million | +54.85% |
| 2022-12-31 | $3.97 Million | +13.21% |
| 2021-12-31 | $3.51 Million | -66.35% |
| 2020-12-31 | $10.42 Million | -6.52% |
| 2019-12-31 | $11.14 Million | +204.86% |
| 2018-12-31 | $3.66 Million | +292.08% |
| 2017-12-31 | $932.34K | -50.51% |
| 2016-12-31 | $1.88 Million | +23.96% |
| 2015-12-31 | $1.52 Million | -76.32% |
| 2014-12-31 | $6.42 Million | +68.35% |
| 2013-12-31 | $3.81 Million | +3.79% |
| 2012-12-31 | $3.67 Million | +16.62% |
| 2011-12-31 | $3.15 Million | +33.71% |
| 2010-12-31 | $2.36 Million | -10.52% |
| 2009-12-31 | $2.63 Million | +139.65% |
| 2008-12-31 | $1.10 Million | -- |
About Predictive Oncology Inc
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D cult… Read more